Items where authors include "Schlichting, M."

Article

Morga, A., Latimer, N.R. orcid.org/0000-0001-5304-5585, Scott, M. et al. (3 more authors) (2022) Is intention to treat still the gold standard or should health technology assessment agencies embrace a broader estimands framework? : Insights and perspectives from the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum. Value in Health. ISSN 1098-3015

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2021) What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Applied Health Economics and Health Policy, 19 (3). pp. 389-401. ISSN 1175-5652

Bullement, A. orcid.org/0000-0001-7091-0972, Willis, A., Amin, A. et al. (3 more authors) (2020) Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 20. 103. ISSN 1471-2288

Kapetanakis, V., Prawitz, T., Schlichting, M. et al. (6 more authors) (2019) Assessment-schedule matching in unanchored indirect treatment comparisons of progression-free survival in cancer studies. PharmacoEconomics, 37 (12). pp. 1537-1551. ISSN 1170-7690

Proceedings Paper

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2019) PCN259 Should health state utility values (HSUVS) in cancer immunotherapies (IOS) be analyzed by time to death (TTD) or progression status? Results of a simulation study. In: Value in Health. ISPOR 2019 : Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier BV , S105-S105.